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I. Introduction     1 
I. INTRODUCTION 
Over the last few decades the use of viruses as vaccine vectors has 
developed an increasingly important role in the field of vaccines in both 
veterinary and human medicine. The main advantages of viruses as a viral 
vector platform are, inter alia, the induction of high levels of antigen-
specific humoral and cellular immune responses without the need of 
additional adjuvant application.  
One of the most promising vectors is the Modified Vaccinia virus Ankara 
(MVA), a replication deficient and safety tested vaccinia virus (VACV) that 
is already licensed as a replacement smallpox vaccine in Europe. 
Furthermore, MVA represents an experimental non-replicating viral vector 
vaccine against various infections and cancer diseases with the objective 
to serve as a vaccine platform for rapid immunization against newly 
emerging pathogens.  
A detailed understanding of MVA’s biological properties is very important 
in terms of its potential as safe viral vector vaccine. Despite having known 
about the presence of a non-plaque forming particle subpopulation in 
purified vaccinia virus stock preparations for decades, the biological 
activities of these virions are still uncertain. In that context we wanted to 
put emphasis on these unknown particles in terms of their infectious 
potential and their ability to pass certain levels of the MVA molecular life 
cycle. 
For this purpose we generated two indicator viruses that visualize the 
early and the late stage of the gene expression of MVA and MVA’s 
ancestor virus Chorioallantois Vaccinia virus Ankara (CVA) via different 
fluorescent signals. After monitoring the dynamic life process of MVA’s 
and CVA’s cascade-like gene expression, we indeed found that the non-
plaque forming particles are biologically active. More precisely, these 
particles are able to enter cells and switch on the first step of the virus 
molecular life cycle. About 10-20% of the single cell infections achieve the 
level of late gene expression. Thus, these data indicate that the non-
plaque forming particle subpopulation might play an important role in 
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triggering the innate and adaptive immune response induced by vaccinia 
virus based vaccines. 
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II. LITERATURE REVIEW 
1. Poxviruses 
1.1. Taxonomy 
 
Two subfamilies of poxviruses make up the family Poxviridae, 
Chordopoxvirinae infect vertebrates and the Entomopoxvirinae infect 
insects. The subfamily of Chordopoxvirinae is divided into nine genera, 
Avipoxvirus, Cervidopoxvirus Capripoxvirus, Leporipxvirus, 
Molluscipoxvirus, Orthopoxvirus, Parapoxvirus, Suipoxvirus, Yatapoxvirus 
and two unassigned species. Within the same genus the viruses show a 
similar host range and morphology along with a phylogenetic relation 
(MOSS, 2013b). The best known genus of the Chordopoxvirinae is the 
genus Orthopoxvirus because of its famous members variola virus, the 
causative agent of smallpox, and vaccina virus (VACV), the close relative 
used as vaccine to eradicate smallpox by the World Health Organization 
between 1958 and 1977 (FENNER et al., 1988). The cowpox virus seems 
to be the ancestral member of this genus, as it possesses all genes 
existent in other Orthopoxviruses, whereas some of these genes are 
absent in the other members (SHCHELKUNOV et al., 1998; MOSS, 
2013b). 
 
1.2. Virion morphology  
 
The Poxviruses’ (POXV) morphology is characterized by an oval to barrel-
shaped architecture. The dimensions of the virions are around 250 nm in 
diameter and 360 nm in length. Thus POXVs belong to one of the largest 
well-studied animal virus families, which can even be visualized by light 
microscopy (figure 1). It is remarkable that POXVs have two infectious 
forms: the mature virion (MV), which contains a single outer membrane, 
and the extracellular enveloped virion (EV), which basically represents an 
MV but additionally possesses a further outer lipid membrane containing 
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unique EV-specific membrane proteins (PAYNE, 1978; ROPER et al., 
1996; LOCKER et al., 2000; MOSS, 2006). Interestingly enough, MVs are 
the most frequent and basic infectious form, but an efficient cell-to-cell 
spread is induced by EVs (BLASCO & MOSS, 1992). 
The biconcave core and the lateral bodies filling the space between the 
outer membrane and the core are the major characteristics of the virion’s 
internal structure. The core encloses the s-shaped POXVs’ genome - a 
linear double-stranded deoxyribonucleic acid (dsDNA) of 130-300 kilobase 
pairs (kb) (MOSS, 1996). The DNA strands are linked by single stranded 
hairpin loops with a high content of adenosine and thymine. Adjacent to 
the termini, there are inverted terminal repeats (ITRs) that include dozens 
of open reading frames (GARON et al., 1978; BAROUDY et al., 1982). 
Here, the localization of the genes exhibit a distinct pattern: Highly-
conserved genes, essential for replication, are usually placed in the central 
region, whereas end terminal genes are often variable genes, which are 
not involved in replication but rather in host interactions (PERKUS et al., 
1990; WERDEN et al., 2008). Further components within the core of the 
POXV particles are virus encoded enzymes and factors which are  
 
 
 
 
 
 
 
 
 
Figure 1: Poxvirus morphology 
(Source: ViralZone; www.expasy.org/viralzone, SIB Swiss Institute of 
Bioinformatics; with permission) 
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essential for the regulation of the early stage transcription, such as the 
multisubunit viral DNA dependent ribonucleic acid (RNA) polymerase and 
the mRNA capping enzymes (KATES & MCAUSLAN, 1967). 
 
1.3. Poxviral diseases 
 
The most well-known poxviral disease is the human smallpox caused by 
the variola virus, a member of the genus Orthopoxvirus. Smallpox, 
triggered by a solely human pathogen, was a dreaded illness which 
reached a mortality rate of up to 40%. The main transmission route was 
via airborne infectious respiratory droplets from variola infected patients. 
The virus first infected the mucosal surfaces of the nasopharyngeal tract 
before it moved on to the regional lymphatics and finally caused a viremia. 
The most common clinical type of variola infection was the ordinary 
smallpox: Here the first typical clinical symptoms were fever, backaches, 
headaches, vomiting and prostration after an incubation period of 7 to 17 
days. This was followed by the appearance of a systemic rash whose 
pattern was centrifugal, mostly concentrated on the oral mucosa, face and 
extremities (FENNER et al., 1988; DAMON, 2013).  
The earliest described cases of smallpox can be traced back to the fourth 
century AD (FENNER et al., 1988). In 1798, Edward Jenner was the first 
to publish the observation of a cross protection between cowpox and 
smallpox and thus he played a pioneering role in vaccine research 
(JENNER, 1798). Cowpox was later replaced by the VACV, which is 
closely related to the cowpox virus. The global vaccination program with 
VACV, commissioned by the World Health Organization (WHO) between 
1958 and 1977, finally resulted in the eradication of smallpox in 1980 
(FENNER et al., 1989). 
Although naturally occurring variola virus is eradicated, humans are still 
faced with POXV diseases as several of the animal pathogenic POXVs 
have zoonotic potentials. In 2003, the U.S. was confronted with an 
outbreak of the monkeypox virus (MPXV) which resulted in 87 reported 
human infection cases (CDC, 2003; LIKOS et al., 2005). These first 
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human infections outside Africa were accidentally transmitted by prairie 
dogs that had had temporarily close contact to MPXV-infected rodents 
which were originally from Ghana (REYNOLDS et al., 2007). Due to the 
rather low virulence of the MPXV strain, there were fortunately no fatalities 
or human-to–human transmissions during this outbreak (REED et al., 
2004). However, the existence of a natural reservoir of more virulent 
strains in rodents in central Africa makes MPXV infections a serious 
zoonotic POXV threat. This is especially true for immunocompromised 
patients and the unvaccinated population born after discontinuation of the 
mandatory vaccination against smallpox (TESH et al., 2004; XIAO et al., 
2005; ESSBAUER et al., 2010). 
Furthermore, POXVs are also pathogens to be feared in industrial 
livestock production, as clearly demonstrated by a recent outbreak of a 
highly-pathogenic fowlpox virus that killed all 10,000 breeding chickens in 
a poultry flock in 2009 (ZHAO et al., 2014). Another example is the 
camelpox virus which has a major economic impact on camel farming due 
to loss in terms of meat and milk production. It effects primarily young 
calves and pregnant female camels and is endemic, for example, in 
Middle Eastern, Asian and African camel-rearing countries (DURAFFOUR 
et al., 2011). 
Due to natural reservoirs of POXVs and the fear of accidental or deliberate 
release of smallpox, coupled with a growing unvaccinated human 
population, POXVs still represent serious pathogens in the fields of human 
and veterinary medicine. 
 
2. Life cycle of vaccinia virus as prototype poxvirus 
2.1. Vaccinia virus entry  
 
Vaccinia virus, the prototype of the genus Orthopoxvirus, played a key role 
in the early scientific research of viruses (FENNER et al., 1989). It was 
among the first viruses evaluated via electron microscopy (BORRIES et 
al., 1938). In addition, it was also among first viruses that could be  
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Figure 2: Cellular cycle of poxvirus infection  
(Source: ViralZone; www.expasy.org/viralzone, SIB Swiss Institute of 
Bioinformatics; with permission) 
 
amplified in cell cultures (PARKER & NYE, 1925; MAITLAND & 
MAITLAND, 1928) and were purified successfully to perform chemical 
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analysis of the virions (PARKER & RIVERS, 1935). As a model virus for 
the genus Orthopoxvirus and for the Poxviridae as well, the vast majority 
of information about POXVs life cycles and the interdependencies of virus-
host interactions have been gained through studies using VACV (MOSS, 
2013b).  
The presence of two infectious forms of POXVs, EV and MV leads to the 
hypothesis of different entry pathways (figure 2). The attachment of the 
MVs is performed via four viral proteins binding glycosaminoglycans and 
laminin on the cell surface (CARTER et al., 2005; MOSS, 2012), followed 
by two feasible cellular entry mechanisms: Either MV’s outer membrane 
immediately fuses with the plasma membrane or the virion is taken up 
more efficiently by an actin-dependent macropinocytosis (CARTER et al., 
2005; MERCER & HELENIUS, 2008). The proteins involved in EV’s 
attachment have not yet been described. An entry-fusion complex, which 
seems to consist of 12 proteins, is known to be involved in the virus-cell 
fusion (SENKEVICH et al., 2005; LALIBERTE et al., 2011; MOSS, 2012). 
As this complex is located in the MV membrane it was suspected that 
removal of the external EV membrane precedes EV cell fusion. This was 
indeed confirmed by electron micrographs of disrupted EV envelopes and 
the fusion of the inner membrane with the plasma membrane of the cell 
(LAW et al., 2006). Although many proteins involved in the virions entry 
are identified, the specific protein receptors have not yet been determined.  
 
2.2. Cascade of gene expression 
 
The POXV life cycle occurs entirely in the host cell cytoplasm without 
using the cellular replication system (MOSS, 1996). Hence, POXV virions 
hold a full transcription system for the regulation of the viral gene 
expression in order to initiate the first step of a cascade-like regulated 
transcription (MOSS, 2013b). This type of genetic programming is 
characterized by a selective expression of early, intermediate and late viral 
genes which is directed by transcription factors that are produced in each 
temporal stage to initiate the next level of gene expression (BALDICK & 
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MOSS, 1993; MCFADDEN, 2005).  
 
Subsequent to the host cell entry of the VACV virions, early gene 
expression starts immediately with a detection of mRNA within 20 minutes 
(SANZ & MOSS, 1999). The early gene products initiate disruption of the 
virus core (“uncoating”), release of the genome into the cytoplasm and 
DNA replication (MCFADDEN, 2005). Cessation of early gene expression 
is regulated tightly due to the existence of specific nucleotide sequences 
serving as transcription termination signals. Early gene expression is 
immediately followed by DNA replication that occurs in specific 
cytoplasmic sites which are known as viral factories (YUEN & MOSS, 
1987). These viral factories are enveloped by rough endoplasmic 
reticulum and can be identified by light and electron microscopic 
autoradiography (DOMI & BEAUD, 2000; SCHRAMM & LOCKER, 2005). 
Cessation of DNA replication coincides with the onset of intermediate 
stage transcription at about 2-3 hours after infection. Here, late stage 
transcription factors, DNA packaging and core associated proteins are 
encoded by the intermediate genes in order to initiate late gene 
transcription right after the termination of the intermediate stage (KECK et 
al., 1990; SANZ & MOSS, 1999). Both the intermediate and the late gene 
transcription are also called post-replicative gene expression, as inhibition 
of DNA replication revealed that the following transcription stages were 
blocked (ROSEL & MOSS, 1985; BROYLES, 2003). Regulation of the late 
gene transcription is not as stringent as the early gene expression since 
late transcription lacks specific termination signals. This in turn results in 
the synthesis of long read-through RNA transcripts and persistence of late 
gene transcription until the virus life cycle is finished (XIANG et al., 1998; 
MOSS, 2013b). 
 
2.3. Assembly, exit and cell-to-cell spread 
 
The earliest assembly stages that can be observed within the viral 
factories are crescent-shaped membrane structures with a honeycomb 
lattice on the surface. These membrane structures form the non-infectious 
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precursor virions of the MV - the so-called immature virions (IV) 
(GRIMLEY et al., 1970; WARD, 2005b). The IVs arise due to the 
absorption of a nucleoprotein mass, including the genome and the early 
transcription apparatus, while the membrane termini seal circularly 
(CONDIT et al., 2006). After that, the spherical IV is transformed into the 
MV which is associated with a disassembly of the lattice scaffold and 
internal restructuring (BROWN et al., 2006). The majority of MVs remain 
as the POXV’s intracellular form within the infected host cell and can only 
be externalized by cell lysis (MOSS, 2013b). However, some MVs pass 
through a wrapping process involving two further membranes which are 
derived from the trans-Golgi network or endosomal cisterna (TOOZE et 
al., 1993; SCHMELZ et al., 1994). These membranes are essential for 
intracellular migration and EV generation. The wrapped-virion moves to 
the cellular periphery via microtubules followed by a fusion with the 
plasma membrane to release the EV (WARD & MOSS, 2001a; SMITH et 
al., 2002; WARD, 2005b). A smaller amount of the externalized EV is 
localized in the medium whereas most externalized EVs adhere to the cell 
surface. The adherent EVs are responsible for efficient cell-to-cell spread 
via actin containing microvilli (CUDMORE et al., 1995) whereas the 
liberated EVs are responsible for the wide range distribution and so 
contribute for the transmission within the host (PAYNE, 1980; 
VANDERPLASSCHEN et al., 1998). In contrast to this the MVs play a key 
role in the transmission between the host animals (MOSS, 2012). 
 
3. Modified Vaccinia virus Ankara 
3.1. Origin from Chorioallantois Vaccinia virus Ankara 
 
The Modified Vaccinia virus Ankara is originated from a strain of VACV 
which was once utilized as a smallpox vaccine by the Turkish government 
(VACV Ankara). There, smallpox vaccine production was mediated by 
virus amplification in donkey-calf-donkey passages. When the virus was 
brought to Munich by Mayr and Herrlich, it was originally passaged on 
chorioallantoic membranes of embryonated chicken eggs and renamed to 
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Chorioallantois Vaccinia virus Ankara (CVA) (MAYR et al., 1975). In 
1954/55, following two amplifications on bovine skin, CVA was also used 
as a smallpox vaccine in Munich. However, due to a rather frequent 
appearance of secondary lesions after primary vaccination the use of CVA 
based vaccines was discontinued (HERRLICH & MAYR, 1957; MAYR et 
al., 1975). In this context Mayr and coworkers analyzed the replicative 
capacity and virulence of CVA in several in vitro and in vivo infections, 
such as in chicken embryo fibroblasts, HeLa cells, rabbits, baby mice and 
embryonated chicken eggs (HERRLICH & MAYR, 1954; MAYR et al., 
1955; MAYR & MUNZ, 1964). These studies determined a wide host 
tropism of CVA, compared it to other strains of VACV, and selected CVA 
for serial passaging experiments in several cell cultures in order to modify 
the host range of the virus (MAYR et al., 1975).  
After 300 serial passages in chicken embryo fibroblasts (CEF) the 
biological properties of CVA had changed more obviously compared to the 
ones determined upon CVA passage in mammalian cells. After another 70 
CEF passages, the CEF-modified CVA strain sustained a loss of the 
typical VACV properties, shown by altered growth capacity in vitro and a 
reduced virulence in vivo such as in rabbits, baby mice and chicken 
embryos (MAYR & MUNZ, 1964). Finally, at passage 516, the CVA-CEF 
descendant virus was named Modified Vaccinia virus Ankara (MVA) in 
order to clearly differentiate it from other attenuated VACV strains and to 
put emphasis on its altered biological properties (HOCHSTEIN-MINTZEL 
et al., 1972). 
Further propagation of MVA through over 570 CEF passages resulted in 
an MVA strain that was confirmed to be avirulent even in 
immunosuppressed animals. These novel and promising properties were 
the impetus to test MVA as a priming vaccine prior to the administration of 
the conventional VACV vaccine in order to improve the safety of smallpox 
vaccination, especially for immunocompromised patients. In clinical field 
trails, 120,000 humans, including individuals at high risk for conventional 
smallpox vaccination, have been successfully vaccinated with MVA 
without the appearance of any significant adverse effects (STICKL et al., 
1974; MAYR et al., 1978). 
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Eradication of smallpox and the end of mandatory vaccinations resulted in 
a loss of interest in improving and developing new and enhanced smallpox 
vaccines. However, in the recent decades the attention increased again 
due to fear of accidental or deliberate release of smallpox. Recent studies 
confirmed MVA’s excellent safety profile, immunogenicity and efficacy 
against Orthopoxviruses in established animal models (DREXLER et al., 
2003; KREMER et al., 2012b; VOLZ et al., 2014) so it was finally licensed 
as a standalone smallpox vaccine in the European Union and Canada 
(VOLLMAR et al., 2006; KENNEDY & GREENBERG, 2009). 
 
3.2. In vivo attenuation and host cell tropism 
 
MVA’s attenuated biological properties are associated with a massive 
restriction of most known VACV virulence and immune evasion factors 
(MEYER et al., 1991; ANTOINE et al., 1998; MEISINGER-HENSCHEL et 
al., 2010). A loss of approximately 15 % of the parental viral genome, 
concerning six large genomic deletion sites and additionally many shorter 
deletions and point mutations, has been identified. The six major 
deletions, which were numbered with Roman numerals I to VI, are located 
in the more terminal regions of the genome, which encode more host 
range regulating genes rather than genes essential for viral replication 
(ALTENBURGER et al., 1989; MEYER et al., 1991). Interestingly enough, 
MVA’s attenuated phenotype is not primarily attributed to the major 
deletions. A recent study showed that CVA mutant viruses containing 
MVA’s six major deletion sites were only able to partly exhibit MVA’s host 
range restrictions in different cell cultures and mice, suggesting that point 
mutations and smaller deletions provide significant contributions to govern 
MVA’s attenuation (MEISINGER-HENSCHEL et al., 2010).  
The comparison of the host range of MVA with the parental CVA strain in 
several cell lines identified three categories of cells: permissive, semi-
permissive and non-permissive cells (DREXLER et al., 1998). The serial 
CEF passaging induced a high restriction of MVA replication on cells of 
avian origin (HOCHSTEIN-MINTZEL et al., 1972). Consequently, the 
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permissive category consists of primary CEF, but remarkably the Syrian 
hamster cell line BHK-21 belongs here as well. However, the BHK-21 cells 
are the only known mammalian cells that support an unimpaired 
replication and spread of MVA. The semipermissive category contains 
African green monkey cell lines such as BS-C-1 and CV-1, which enable 
limited spread of MVA. Nevertheless, most mammalian cells including 
human cells are classified into the non-permissive category. Here, MVA 
shows an inability to replicate productively, although it still remains 
infectious for the cells (CARROLL & MOSS, 1997). Despite this growth 
deficiency early, intermediate and late gene expression is not restricted. 
Due to a late block in the virus’ assembly of viral particles MVA is not able 
to produce infectious progeny. Instead, only immature virions are formed 
in these non-permissive cells (SUTTER & MOSS, 1992). 
Even though MVA’s growth deficiency in different cell lines has been 
intensively evaluated, the genetic background is not yet completely clear. 
So far, Orthopoxviruses comprise five known major host range genes: 
C12L (SPI-1) (ALI et al., 1994), CP77 (GILLARD et al., 1985; HSIAO et 
al., 2006), C7L (PERKUS et al., 1990; OGUIURA et al., 1993), K1L 
(PERKUS et al., 1990) and E3L (CHANG et al., 1995; BEATTIE et al., 
1996). As the CP77 is fragmented in all known VACV strains, this host 
range gene does not contribute to MVA attenuation. Apart from K1L and 
SPI-1 the other genes are still intact in the MVA genome (CARROLL & 
MOSS, 1997). In VACV and MVA the absence of K1L and C7L led to 
abortive replication in most mammalian cell lines (BACKES et al., 2010), 
while introducing K1L in MVA correlated only with multiplication in rabbit 
kidney derived RK-13 cells (SUTTER et al., 1994a; ZWILLING et al., 
2010). The reconstruction of SPI-1 restored MVA propagation only in A549 
(adenocarcinomic human alveolar basal epithelial cells) (WYATT et al., 
1998). Furthermore, an MVA mutant lacking the host range gene E3L, 
which encodes the double stranded RNA-binding protein E3, showed a 
severe deficiency in viral DNA replication and late gene expression in 
human HeLa cells (LUDWIG et al., 2005). 
Still, the POXVs cellular tropism results from the interactions of two 
factors: viral host range genes and, in addition, intracellular factors. These 
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cellular components have long been unknown, but a recent study using 
RNA interference screens revealed highly-conserved cellular proteins that 
may act as restriction factors for poxviral multiplication (SIVAN et al., 
2015; VOLZ et al., 2015b). These data shed new light on the virus host 
interactions. 
MVA’s in vitro attenuation is also evident in vivo. It is mainly presented by 
the cessation of the typical VACV virulence character, which is particularly 
noticeable in humans, as demonstrated in the clinical human field trails 
mentioned above (STICKL et al., 1974; MAYR et al., 1978). Furthermore, 
MVA vaccination studies in several animal models such as dogs, piglets, 
rabbits, calves and macaques did not show the appearance of any 
significant adverse effects (MAYR et al., 1975). In addition, it has been 
reported that MVA was cleared within 48 hours after intraperitoneal 
infection of mice and that MVA was even found to be avirulent in newborn 
and irradiated mice (MAYR et al., 1978; MEYER et al., 1991; RAMIREZ et 
al., 2000). It is remarkable that MVA was even successfully tested in a 
preclinical safety study with immune-suppressed macaques. No clinical or 
pathological signs were found to be associated with the inoculation of high 
doses of MVA. In addition, infectious MVA could not be reisolated from 
these macaques (STITTELAAR et al., 2001). In contrast, generalized 
VACV infections could be observed in immunosuppressed (HIV positive) 
individuals, which were vaccinated with VACV vaccines (REDFIELD et al., 
1987). Moreover, severe post vaccination complications could also be 
observed in VACV vaccinated infants during the eradication of smallpox 
(GURVICH, 1992). Thus, particularly with regard to immunocompromised 
or potentially immunocompromised individuals, such as infants and 
elderly, MVA seems to have an excellent safety profile to be used as a 
platform for recombinant human vaccines (STITTELAAR et al., 2001). 
 
3.3. Development as vaccine platform 
 
In 1983/84 recombinant VACV was the first virus that was established to 
express foreign antigens in order to induce immunity against other 
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pathogens (SMITH et al., 1983; MOSS et al., 1984; DRAPER & HEENEY, 
2010). Since then, various viral vectors were generated as potential 
vaccine platforms, such as adenoviruses and alphaviruses 
(LUNDSTROM, 2005; CHOI & CHANG, 2013). An advantage to utilizing 
viral vectors as vaccine antigen carriers is their ability to infect cells. This 
allows for intracellular antigen production which results not only in a 
humoral immune response, but also in a strong cell-mediated immune 
response by activating antigen-specific CD8+ T cells (DRAPER & 
HEENEY, 2010). Furthermore, viral components trigger the adaptive 
immunity by inducing inflammatory reactions, which usually make the 
application of adjuvants unnecessary. In contrast to this, other vaccines, 
such as protein subunits or DNA vaccines, often need additional adjuvants 
to enhance immunogenicity (URA et al., 2014). 
VACVs are ideally suited for the application as viral vector vaccine 
platform, due to the following biological properties: I. The large genome 
enables the insertion of large or even several foreign genes without 
affecting VACV infectivity; II. The life cycle occurs entirely in the cytoplasm 
outside the cellular nucleus, without any integration in the host genome; 
III. Depending on the selected promoter, high levels of foreign antigens 
can be produced in each phase of the life cycle for the induction of a 
strong adaptive immune response (MOSS, 1996). However, typical side 
effects of viral infections and even severe adverse reactions, which were 
observed during the smallpox eradication campaign, shifted the attention 
to the use of attenuated VACVs as vaccine platform (LANE et al., 1969; 
KENNEDY et al., 2009). Fortunately, it turned out that a reduced virulence 
is not always linked to an impaired immunogenicity. Indeed, it has been 
shown that MVA induced even a greater vaccination efficacy in mice and 
in non-human primates in comparison to replication competent VACV 
vector vaccines (SUTTER et al., 1994b; HIRSCH et al., 1996; RAMIREZ 
et al., 2000).  
Sutter and Moss were the first who successfully evaluated the use of MVA 
as an expression vector. Furthermore, they determined that MVA 
expresses early genes as well as late genes in human cells, while the 
virion assembly is blocked (SUTTER & MOSS, 1992).This allows efficient 
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protein expression even under non-permissive conditions. Another 
attenuated VACV, the New York attenuated Vaccinia virus (NYVAC) 
generated by deleting specific regions in the genome of the VACV strain 
Copenhagen, synthesize only some of the late viral proteins in human 
cells (TARTAGLIA et al., 1992; PAOLETTI, 1996; NAJERA et al., 2006). In 
comparison to MVA this might constitute an adverse property in terms of 
high-level antigen production. 
MVA, as a promising viral vaccine platform, is characterized by its proven 
safety and unimpaired gene expression in mammalian cells, but also by its 
high level of immunogenicity and protective capacity (SUTTER & MOSS, 
1992; MOSS et al., 1996; STITTELAAR et al., 2001). The strong 
immunogenicity triggered by MVA is associated with the loss of several 
immune evasion factors. Unlike other VACVs, MVA can only produce a 
few of the receptor-like proteins that inhibit host cytokines, such as type I 
and type II interferon (BLANCHARD et al., 1998; WAIBLER et al., 2007). 
Unaffected secretion of the host cytokines initiates the expression of 
antiviral proteins which may contribute to the efficacy of a vaccine virus 
(BLANCHARD et al., 1998). Another MVA specific feature is the induction 
of an early immigration of CD4+ lymphocytes, monocytes and neutrophils 
to the site of infection via the cytokine CCL2 (LEHMANN et al., 2009). 
MVA’s proven immunogenicity, its safety profile as well as the established 
methods for large scale production provide excellent characteristics for the 
application as a viral vector vaccine (KREIJTZ et al., 2013). It is, thus, not 
surprising that over the last decade several MVA-based candidate 
vaccines have been widely tested in phase I and phase II clinical trials in 
the field of both veterinary and human medicine (KREIJTZ et al., 2013). In 
human medicine the ongoing research focuses particularly on the 
development of MVA-based viral vector vaccines against newly emerging 
infectious diseases, such as MERS, West Nile and Influenza, but also 
against infections that have presented major health challenges for years, 
such as AIDS, tuberculosis and malaria (GILBERT, 2013; KREIJTZ et al., 
2013; VOLZ & SUTTER, 2013). 
For instance, a recombinant MVA candidate vaccine against influenza A 
viruses of subtype H5N1 (MVA-HA-VN/04) has been proven to be highly 
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protective in preclinical mouse and macaque studies after the challenge 
with homologous and heterologous H5N1influenza viruses (KREIJTZ et 
al., 2007; KREIJTZ et al., 2009a; KREIJTZ et al., 2009b). These promising 
results allowed for a phase I/IIa clinical trial with 80 young volunteers. The 
vaccination resulted in high titers of H5N1 specific antibodies. Interestingly 
enough, a further booster vaccination after 12 months induced an increase 
of H5-specific antibodies despite the presence of MVA specific antibodies 
that emerged during the previous vaccination (KREIJTZ et al., 2014). 
Thus, this study confirmed that MVA has a great potential as a viral 
backbone for recombinant influenza vaccines. 
Furthermore, a recombinant MVA candidate vaccine (MVA-MERS-S) 
against the newly emerged Middle East respiratory syndrome coronavirus 
(MERS-CoV) could be generated within a year after the new disease was 
first described in 2012 (ZAKI et al., 2012; SONG et al., 2013). Two years 
later in 2015, protective efficacy of MVA-MERS-S was confirmed in a 
preclinical mouse study after the challenge with MERS-Co-V (VOLZ et al., 
2015a). This was followed by a collaborative study to demonstrate efficacy 
of vaccination in dromedary camels, which was published in 2016. The 
authors showed a highly significant reduction of viral load in the excretions 
of vaccinated and subsequently-challenged dromedaries, which are 
thought to mediate MERS-CoV transmission to humans (HAAGMANS et 
al., 2016). The brief time span between the first description of MERS-CoV 
and the availability of a recombinant MVA candidate vaccine against this 
previously unknown pathogen demonstrates the efficiency of MVA as a 
vaccine platform against emerging infectious diseases.  
 
4. Engineering recombinant MVA and use of 
fluorescent proteins in scientific research 
 
4.1.   Engineering recombinant MVA 
 
Generally, recombinant MVAs are generated by using the well-established 
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methodology of homologous DNA recombination in infected cells, which is 
a common occurrence during poxvirus replication (0.1%) (BALL, 1987; 
KREMER et al., 2012a). For recombinant engineering, the recombination 
event is directed by an MVA transfer plasmid. In order to ensure 
successful results, the MVA transfer plasmid has to contain certain 
components: the foreign gene sequence(s) of interest, a VACV promoter 
for the regulation of the foreign gene expression, a selection marker gene 
to facilitate isolation of recombinant MVA and two genomic MVA flanking 
sequences. These flanking sequences precede and follow the marker 
sequence as well as the gene of interest in order to enable homologous 
recombination to the selected MVA insertion site (KREMER et al., 2012a).  
The strength of foreign gene expression is decisively influenced by the 
selected promoter. Several natural and synthetic virus-specific promoters 
that are assigned to the early, intermediate or late phase of gene 
expression are available (BROYLES, 2003; WYATT et al., 2008). 
However, there are also promoters that have activity in both early and late 
transcriptional stages, such as P7.5 (COCHRAN et al., 1985) and the 
modified promoter H5 (PmH5) (WYATT et al., 1996). It has been shown 
that the timing of gene expression induces different kinds of immune cells: 
Early VACV gene products seem to be preferentially targeted by 
CD8+ T cells, while intermediate and late gene products are 
predominantly recognized by CD4 T cells and specific antibodies 
(MOUTAFTSI et al., 2007; MOUTAFTSI et al., 2010; YANG et al., 2011). 
Therefore, tandem early and late promoters are commonly used to 
achieve high levels of foreign gene expression during the whole virus life 
cycle in order to induce a strong immune response (WENNIER et al., 
2013).  
A variety of different selection techniques to isolate recombinant MVAs are 
available. Early methodology relied on the use of VACV host range gene 
K1L whereby its acquisition in MVAs genome correlates with the ability to 
grow in rabbit kidney RK-13 cells (SUTTER et al., 1994a). Here, the VACV 
K1L gene is located next to the gene of interest within the transfer 
plasmid. Homologous recombination between the wild type MVA and the 
transfer plasmid results in a recombinant MVA expressing both the 
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recombinant antigen and K1L. This enables recombinant MVA to grow in 
RK-13 cells and ease the clonal isolation. Repetitive DNA sequences 
within the K1L expression cassette, allow K1L removal under nonselective 
growth permission, such as in MVA permissive Chicken embryo 
fibroblasts. This method of transient host range selection on RK-13 cells is 
well-established. However, the use of RK-13 cells may be restricted as 
recombinant MVAs generated in these cells have no record for clinical use 
(KREMER et al., 2012a). 
Another more recent selection technique is based on the use of transiently 
expressed fluorescent markers, such as the green fluorescent protein 
(GFP). This technique has major advantages: I. The use of selecting 
agents and substrates is unnecessary; II. The recombinant MVA can be 
generated in CEF cells even without the addition of serum, III. The 
selection of recombinant MVA is easily possible via fluorescent 
microscopy. Similar to transient host range gene selection, the fluorescent 
reporter gene is located between repetitive DNA sequences, which allow 
for its removal in further rounds of plaque purification (KREMER et al., 
2012a). 
In order to verify successful isolation of recombinant MVA, proper quality 
controls including assays for genetic identity, replication deficiency and 
stable foreign gene expression are essential.  
Generally, genetic stability can be analyzed by PCR monitoring. Foreign 
genes inserted in one of the characteristic six major deletions of the MVA 
genome are identified by using oligonucleotide primers that target the 
regions of the major deletions respectively (MEYER et al., 1991). Thus, 
the non-presence of wild type MVA and the correct insertion of foreign 
genes are easily proven. Stable expression of foreign genes can be 
evaluated on protein level via Western blot analysis. In some cases 
recombinant gene products interfere with the replication of recombinant 
MVA which could allow for generation of the wild type MVA. In this context 
serial cell culture passages at a low multiplicity of infection are used to 
confirm the stability of foreign gene expression. As replication deficient 
MVA can be handled under the biosafety level 1, it is also necessary to 
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test the replication capacity of recombinant MVA in comparison to the wild 
type MVA in permissive and non-permissive cells (KREMER et al., 2012a).  
Taken all together the methods for generation and characterization of 
recombinant MVA are well-established and allow for rapid generation of 
recombinant MVA vaccines with the capability of large scale productions. 
 
4.2.   Fluorescent proteins 
 
The discovery of the green fluorescent protein (GFP) (SHIMOMURA et al., 
1962) revolutionized a large field of research related to processes in living 
cells and organisms. In the field of virology fluorescent proteins became 
unique instruments with a broad range of applications in many 
experimental settings, such as in studies of viral life cycle, in vivo tropism, 
pathogenesis and viral host cell interactions (WARD & MOSS, 2001a; DE 
VRIES et al., 2010; FUKUYAMA et al., 2015). 
In 1962, Shimomura was the first to isolate GFP from the jellyfish Aequora 
victoria. He discovered the GFP along with the separate luminescent 
protein aequorin in the light producing organs of the jellyfish. Here, GFP 
absorbs the blue light (maximum 395 nm) produced by the protein 
aequorin and in turn exhibits the bright green fluorescence (maximum 509 
nm) (SHIMOMURA et al., 1962). After 30 years, Douglas Prasher 
succeeded in sequencing and cloning of GFP, which allowed for large 
scale production of the fluorescent protein (PRASHER et al., 1992). The 
suitability of GFP as a marker to study gene expression and protein 
localization in living organisms was not reported until two years later 
(CHALFIE et al., 1994). Today a large redundant of GFP variants that are 
achieved through protein engineering are available. Due to mutations that 
affected the spectral characteristics of GFP, many variants with emission 
spectral profiles of blue, cyan and yellow emerged. One of the most-used 
wild type GFP variants is the enhanced GFP. It is an improved type in 
terms of a brighter and stronger green fluorescence in mammalian cells 
(ZHANG et al., 1996). The isolation of other GFP-like proteins from 
II. Literature Review     21 
nonbioluminescent Anthozoa species finally brought about fluorescent 
proteins emitting light in the red spectral region in 1999 (MATZ et al., 
1999). 
Regardless of their originating species, GFP-like proteins consist of 11 
strands of beta sheet that form a barrel-like structure by surrounding an 
alpha helix. The chromophore, the part responsible for the light emission, 
is placed within the alpha helix (YANG et al., 1996). The fluorescent 
proteins derived from Aequora victoria have a naturally weak dimerization 
tendency. In contrast to this virtually all fluorescent proteins derived from 
Anthozoa species form stable tetrameric complexes, which bring about 
difficulties in experimental settings in cells (BAIRD et al., 2000; 
CAMPBELL et al., 2002). The oligomerization tendency often leads to 
formation of intracellular aggregations with the targeted proteins. In order 
to improve the usage of Anthozoa fluorescent proteins as general 
fluorescence tags, efforts were made to develop monomeric complexes 
(CAMPBELL et al., 2002). Protein engineering led to the generation of 
Anthozoa monomer derivatives with distinct fluorescences and altered 
wavelengths, such as mCherry (SHANER et al., 2004), mRaspberry 
(WANG et al., 2004b), mPlum (WANG et al., 2004b), and mGrape 
(SHANER et al., 2004). It turns out that mCherry is the most beneficial and 
commonly used of these red monomers (SHANER et al., 2005; DAY & 
DAVIDSON, 2009). 
 
4.3.   Use of fluorescent proteins in scientific research 
 
Fluorescent proteins became important tools for numerous applications in 
the research of complex biological living systems. In the field of virology 
these fluorescent markers allow study of the biological properties of the 
viruses in cells, tissues and even entire organisms by using live imaging 
techniques (WARD & MOSS, 2001a; DE VRIES et al., 2010; FUKUYAMA 
et al., 2015). 
Tracking fluorescence labeled viruses revealed new insights on their 
biodistribution in different animal models. Here, the expression of 
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fluorescent signals by recombinant viruses enables us to follow the course 
of infection and viral spread by using fluorescence macroscopic-imaging 
techniques. There have been many fluorescent tracking experiments with 
various viruses. For instance, the use of this method allowed the 
identification of lymphocytes as target cells for canine distemper virus 
(VON MESSLING et al., 2004). Also new findings about the cell tropism of 
measles infections in macaques could be determined (LEMON et al., 
2011). 
Furthermore, a widely used feature of fluorescent proteins is their ability to 
label proteins within cells and organisms in order to track the target 
proteins from expression through to degradation in real time. In virology 
this application is based on the generation of recombinant viruses which 
express fluorescent signals that are fused to the gene of interest. The site 
of fusion, which can be either at the protein’s termini or inside the protein’s 
chain, has to be well deliberated to prevent effects on the target protein’s 
localization, targeting and function. Furthermore, the choice of a suitable 
fluorescent protein is also very important: it should not interfere with the 
characteristics of the target protein (CHUDAKOV et al., 2010) and it 
should produce a sufficient signal for reliable imaging in cells and tissues 
that have a strong auto fluorescence (RICH et al., 2014). Due to 
fluorescent fusion proteins it is possible to reveal information on a protein’s 
movement and association with cellular components. For example, the 
use of GFP fusion proteins containing (I) MV-specific surface protein A27 
or (II) the EV-specific B5-R membrane protein, demonstrated that VACV’s 
intracellular EVs and MVs use microtubules for the intracellular transport 
(WARD & MOSS, 2001b; WARD, 2005a).  
In addition to protein labeling, the gene regulatory network can be 
analyzed by using fluorescence imaging for monitoring the promoters’ 
strength and activities as well (CHUDAKOV et al., 2010). The level and 
time of fluorescence expression concerning the regulation through a 
certain promoter can be determined, for example, via flow cytometry (DI 
PILATO et al., 2013). As fluorescent signals are typically stable for many 
hours, there are even destabilized fluorescent proteins available. Due to 
the fact that these proteins have a short time of maturation and 
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degradation, it is possible to precisely track the promoter’s activation 
period in real time. (LI et al., 1998; CHUDAKOV et al., 2010). 
Another unique application of GFP consists in its utilization as a model 
antigen in viral vector systems. Like other antigenic peptides, GFP-derived 
peptides are also presented by the major histcompatibility complexes. This 
in turn results in a GFP-specific CD8+ T cell immune response. Due to the 
availability of a GFP-epitope-specific peptide, it is easily possible to 
identify GFP-specific CD8+ T cells via ELISpot Assay (GAMBOTTO et al., 
2000). GFP as a model antigen has been proven to be very useful in 
studying different antigen modifications on immunogenicity. This was 
nicely shown by a recent study that analyzed the GFP-specific CD8+ T cell 
response of different antigen localizations in the subcellular compartments 
(MARR et al., 2016).  
So far, fluorescent proteins have been successfully established as 
excellent tools concerning analyzing virus host interactions, virus life 
cycles and the biodistribution as they enable the illustration of biological 
processes during viral infections in various in vitro and in vivo studies.
III. Objectives     24 
III. OBJECTIVES  
 
In the view of the importance of MVA-based vector vaccines in clinical use 
as well as the need of a characterization of recombinant MVA candidate 
vaccines in terms of their purity, infectivity and recombinant gene 
expression this work describes the following: 
 
(I)  the generation of recombinant MVA and CVA expressing two 
fluorescent reporter proteins regulated by stage specific promoters 
(II) characterization of both reporter viruses 
 - genetic analysis  
 - protein expression and replication analysis 
 - determination of the relation between the plaque-forming units and                              
  total virus particles in purified preparations of the reporter viruses 
(III) characterization of vaccina virus infections with the reporter viruses 
 - monitoring the vaccinia virus life cycle 
 - evaluation of the relation between single cell infection and plaque  
  formation in MVA permissive cells 
 - tracking single cell infection via live cell imaging 
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IV. RESULTS 
The manuscript is presented in form accepted for publication (Lülf 2016 
Virology, in press). 
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In cell culture infections with vaccinia virus the number of counted 
virus particles is substantially higher than the number of plaques 
obtained by titration. We found that standard vaccine preparations of 
recombinant Modified Vaccinia virus Ankara produce only about 20-
30% plaque-forming virions in fully permissive cell cultures. To 
evaluate the biological activity of the non-plaque-forming particles, 
we generated recombinant viruses expressing fluorescent reporter 
proteins under transcriptional control of specific viral early and late 
promoters. Live cell imaging and automated counting by fluorescent 
microscopy indicated that virtually all virus particles can enter cells 
and switch on viral gene expression. Although most of the non-
plaque-forming infections are arrested at the level of viral early gene 
expression, we detected activation of late viral transcription in 10-
20% of single infected cells. Thus, non-plaque-forming particles are 
biologically active, and likely contribute to the immunogenicity of 
vaccinia virus vaccines. 
 
Vaccinia virus (VACV) is the best-studied poxvirus and the prototype live 
virus vaccine used to eradicate human smallpox (for review see (MOSS, 
2013b)). VACV was among the first animal viruses to be cultured and 
purified (STEINHARDT et al., 1913; PARKER & NYE, 1925; MAITLAND & 
MAITLAND, 1928; PARKER & RIVERS, 1935). Early studies with virus 
preparations from the skin of infected rabbits (STEINHARDT et al., 1913) 
or the chorioallantois membrane (CAM) of embryonated chicken eggs 
(DUMBELL et al., 1957) already provided evidence that more total 
particles (also called “elementary bodies”) are produced than infectious 
VACV virions. Indeed, a ratio of 10 total particles to 1 plaque-forming unit 
(PFU) was determined for purified preparations of VACV using a protocol 
of ultracentrifugation through sucrose-gradient similar to the one still used 
for producing vaccine preparations (JOKLIK, 1962). A single study using 
semi-purified (removal of cellular debris from virus harvest via low-speed 
centrifugation) MVA and comparing EM counted particles to tissue culture 
infectious dose 50 (TICD50) determined 2-3-fold more total particles than 
the TICD50 (GUGGENBERGER, 1989). This biological phenomenon is 
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true for many animal viruses, and even when disregarding morphologically 
or biochemically “incomplete” virions, 10 to 1 million virus particles are 
usually needed to initiate a single event of infection (ISAACS, 1957). 
With a ratio of about 1:10 for CAM infections and tissue culture plaques, 
VACV has one of the highest ratios of virus infections to particles (JOKLIK, 
1962; GALASSO & SHARP, 1963). Interestingly, early experiments 
suggested that the greater fraction of the non-plaque-forming VACV 
particles enter cells and are infectious in tissue culture (GALASSO & 
SHARP, 1964). Yet, it remained obscure whether these infections were 
able to initiate the virus life cycle, switching on gene expression and 
protein synthesis. Furthermore, the prevalence of non-plaque-forming 
particles in VACV vaccine preparations and their possible influence on 
immunogenicity or vaccine efficacy are largely unknown.  
Today, more than three decades after eradicating smallpox as a natural 
disease, VACV is still needed as a reserve vaccine against smallpox due 
to the threat of bioterrorism (MOSS, 2011). Moreover, the virus is 
successfully used as a vector for developing new vaccines against other 
diseases (MACKETT et al., 1982; PANICALI & PAOLETTI, 1982). 
However, the VACV vaccines used during the smallpox eradication 
campaign would be currently considered to have an unsatisfactory safety 
profile, and safer strains of VACV such as Modified Vaccinia virus Ankara 
(MVA) have been established for vaccine development (for review see 
(MOSS, 2013a)).  
MVA was obtained by extensive serial passaging of VACV strain Ankara in 
chicken embryo fibroblasts (CEF), resulting in DNA deletions and 
mutations at multiple sites of the viral genome (MAYR & MUNZ, 1964; 
MEYER et al., 1991; ANTOINE et al., 1998). MVA lost its ability to 
productively replicate in most mammalian cells, but maintained expression 
of all classes of viral and recombinant genes under conditions of non-
permissive viral growth. Therefore MVA can serve as an exceptionally 
safe live viral vector vaccine (SUTTER & MOSS, 1992). Multiple 
recombinant MVAs are currently undergoing clinical testing for vaccination 
against various human infections including AIDS, tuberculosis, and 
malaria (for reviews see (GILBERT, 2013; GOMEZ et al., 2013)). Critically, 
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recent candidate MVA vaccines are being developed for experimental 
immunization of humans against emerging infections such as highly 
pathogenic avian influenza virus H5N1, the Middle East Respiratory 
Syndrome, West Nile fever, or Ebola hemorrhagic fever (KREIJTZ et al., 
2014; VOLZ et al., 2015b; EWER et al., 2016; VOLZ et al., 2016).  
As the clinical use of MVA vector vaccines expands more, vaccine 
preparations require non-clinical characterization for lot consistency, 
purity, infectivity, and recombinant gene expression. Our experience and 
that of others have indicated that the biological properties of the purified 
MVA particles in these preparations are generally unknown. More 
fundamental questions pertaining to the regulation of host-restriction and 
gene expression, as well as practical questions such as MVA vaccine 
immunogenicity also remain unclear. 
Here, we studied recombinant MVA, and found over 70% non-plaque-
forming virions in standard MVA vaccine preparations from avian cell lines. 
Specifically, we were able to monitor the ability of these virions to infect 
different host cells and activate viral gene expression using reporter 
viruses expressing fluorescent proteins under the control of early and late 
viral promoters. The resulting single cell infections synthesized early, and 
to a lesser extent late gene products. For comparison we also analyzed 
the particle properties and infection progression of recombinant virus 
preparations based on the fully replication competent parental VACV 
Ankara strain CVA152. 
 
Non-plaque-forming virus particles in recombinant MVA vaccines 
To characterize the particle content of standard MVA vaccine preparations 
we selected a sucrose-cushion purified preparation of an MVA candidate 
vaccine producing the Ebola virus glycoprotein (MVA-EBOV-GP) obtained 
from clonal isolation by plaque purification. First, to obtain standardized 
counts of total particles we used a virus counter device (ViroCyt Virus 
Counter 3100) known to be used for quality control monitoring by vaccine 
manufacturers. Virus counting is based on flow cytometry using two 
different fluorescent dyes to stain and co-localize proteins and nucleic 
IV. Results     29 
acids. For the MVA-EBOV-GP preparation we counted a total of 1.6 
x10^10 virus particles (VP)/ml (Fig. 1A). In comparison, infectious virus 
particles quantified by plaque titration resulted in 4.8 x10^9 plaque-forming 
units (PFU)/ml, approximately 30% of the total virus particle count in this 
virus preparation.  
The above data are in line with previous results from particle counts by 
electron microscopy, suggesting considerable fractions of non-plaque-
forming particles are present in VACV preparations.  
 
Monitoring the VACV life cycle with reporter viruses expressing fluorescent 
proteins 
To investigate the biological properties of non-plaque forming VACV 
particles in more detail, we constructed the recombinant viruses MVA-
GFP-mCherry and CVA-GFP-mCherry as reporter viruses (Fig. 1B). CVA-
GFP-mCherry served to directly compare MVA to a fully replication-
competent VACV, by using the Ankara strain CVA152 as a true ancestor 
virus of MVA. These recombinant viruses were designed to monitor the 
infection cycle by visualizing key steps in viral gene expression, detected 
through the synthesis of fluorescent marker proteins. Early GFP 
production should indicate virus entry and transcription of viral early 
genes; the detection of red fluorescent mCherry protein (late-mCherry) 
should signal the start of DNA synthesis and viral late gene expression.  
The viruses were quality controlled by PCR analysis, confirming the stable 
integration of the GFP encoding sequences at the I8R/G1L intergenic site 
and mCherry sequences at deletion site III of both MVA and CVA152 
genomes (Fig. 1B; Fig. S1; data not shown). Both recombinant viruses 
were genetically stable, and tested for growth, as well as production of 
recombinant GFP and mCherry proteins as detected by Western blot 
analysis (Fig. S2; data not shown). As expected, MVA-GFP-mCherry 
replicated efficiently in avian CEF and DF-1 cells but not in human HeLa 
or HaCat cells.  
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Fig. S1 Genetic integrity and genetic stability of MVA-GFP-mCherry. 
(A) PCR analysis of MVA-GFP-mCherry viral DNA using oligonucleotide 
primers flanking the six major deletions. (B) PCR analysis of MVA-GFP-
mCherry viral DNA using oligonucleotide primers flanking the I8R/G1L 
insertion site. 
 
To test the activity of our reporter viruses after tissue culture infection, we 
examined the production of the fluorescent proteins GFP and mCherry in 
chicken (CEF and DF-1) or human cells (HaCat and HeLa) by 
fluorescence microscopy (Fig. 1C). At 24 hours post infection (hpi), 
microscopy revealed foci in MVA-GFP-mCherry infected CEF and DF-1 
cells; red fluorescent cells in the center were surrounded by green 
fluorescent cells, marking the early and late phases of the MVA infection. 
In contrast, in HeLa and HaCat cells we detected single green or red 
fluorescent cells, but no formation of plaques or foci with fluorescent cells.  
Productive CVA-GFP-mCherry infections resulted in typical VACV plaques 
visible 24 hpi in all four cell cultures. Again red late-mCherry producing 
cells accumulated in the centers of large virus plaques, while green early-
GFP synthesis was found around the periphery of the plaques. These 
results provided reasonable proof of principle for using these recombinant 
viruses to visualize various productive and abortive infection events in 
tissue culture. 
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Fig. S2 Protein expression and replication analysis.  
(A) Western blot analysis of total cell extracts from primary chicken 
embryo fibroblasts infected with MVA-GFP-mCherry or MVA wildtype at an 
m.o.i. of 10 without (-) or with (+) AraC, 24 hpi. (B) Cells were infected at 
an m.o.i. of 0.001 for multi-step growth analysis, and at an m.o.i. of 5 for 
one-step growth analysis. The cell cultures were harvested at the 
indicated time points and virus yields were determined by back titration 
and counting immunostained foci using a plaque assay. The average 
values of two independent experiments with double titrations are shown. 
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Fig. 1. Monitoring non-plaque-forming virus particles and gene 
expression with reporter fluorescent proteins.  (A) Plaque forming 
units (PFU) and total virus particles (VP) in sucrose-cushion purified stock 
preparations of an MVA recombinant candidate (MVA-EBOV-GP) vaccine 
were quantified via plaque assays (PFU/ml) and virus Counter 
measurement (VirusCounter 3100-ViroCyt) (VP/ml). *Ρ<0.05. (B) 
Schematic diagram of the MVA F6 and CVA152 genome indicating the 
I8R/G1L site, used to insert GFP regulated by the early vaccinia promoter 
Pvgf and the deletion III site used to insert mCherry under the 
transcriptional control of the late vaccinia promoter P11. (C) Fluorescence 
imaging of CEF, DF-1, HaCat and HeLa cells infected with MVA-GFP-
mCherry and CVA-GFP-mCherry at an m.o.i of 0.005 at 24 hpi. 
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Infections with MVA-GFP-mCherry reveal numerous single cell infections 
without plaque formation 
Again using standard sucrose-cushion purified preparations of MVA-GFP-
mCherry and CVA-GFP-mCherry, we determined total virus particle 
numbers by particle counting, and measured infectivity by plaque titration 
(Fig. 2A). In agreement with our data above this analysis also revealed at 
least 3-fold more total particles than PFU. In detail, Virus Counter 
measurements recorded 1.5 x10^10 VP/ml for MVA-GFP-mCherry and 
2.3x10^10 VP/ml for CVA-GFP-mCherry. In contrast, the plaque forming 
units as quantified by plaque titration amounted to 3.8x10^9 PFU/ml 
(~25% of the total particles) for MVA-GFP-mCherry and 3.5x10^9 PFU/ml 
(~15% of the total particles) for CVA-GFP-mCherry.  
To monitor infection events in cell cultures permissive for productive virus 
replication, we analyzed the kinetics of GFP and mCherry expression 
upon MVA-GFP-mCherry infection in CEF and DF-1 cells (Fig. 2B). GFP 
and mCherry expression detected by fluorescence microscopy mostly 
revealed single green fluorescent cells at 12 hpi. At 14 hpi some of the 
single green cells shifted to red fluorescence, and adjacent cells started to 
show green fluorescence, forming foci of infected cells. MVA-GFP-
mCherry formed more even and rounder plaques in DF-1 cells than the 
plaques in CEF, which were more irregularly shaped, corresponding to the 
well-known MVA plaque phenotypes in these cell cultures (Kremer et al., 
2012). By 18 hpi we readily observed growing MVA-GFP-mCherry plaques 
in the cell monolayers, but the majority of the monitored single green 
fluorescent cells neither changed to red fluorescence nor developed into 
new virus plaques until 40 hpi.  
The time point 24 hpi seemed suitable for determining the ratio of single 
infected cells to virus plaques in CEF and DF-1 after MVA-GFP-mCherry 
infection (Fig. 2C). Single fluorescent cells and virus plaques in 96-well 
cell monolayers were automatically quantified (Keyence Hybrid Cell Count 
Module, BZ-H3C). In both chicken cell cultures about 20-30% of all 
detected fluorescent events were identified as viral plaques. However, 
most of the infection events (>70%) were detected as single fluorescent 
cells. After imaging we fixed the infected cell cultures and performed a  
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Fig. 2. Analysis of the MVA life cycle using the reporter virus.         
(A) Plaque forming units (PFU) and total virus particles (VP) in sucrose-
cushion purified stock virus preparations of MVA-GFP-mCherry and CVA-
GFP-mCherry were measured via plaque assays (PFU/ml) and virus 
Counter measurement (VirusCounter 3100-ViroCyt) (VP/ml). **Ρ<0,01; 
***Ρ<0,001. (B) Time course of plaque development. CEF and DF-1 cells 
were infected with MVA-GFP-mCherry at an m.o.i. of 0.005. Infection 
events were monitored via fluorescence imaging in two hours increments. 
(C) CEF and DF-1cells grown in 96-well plates were infected with MVA-
GFP-mCherry at an m.o.i. of 0.01. The wells were imaged via 
fluorescence microscopy at 24 hpi (left panel) and a VACV-specific 
immunostaining plaque assay was performed as a control (middle panel). 
Single infected fluorescent cells and plaques were quantified using Hybrid 
Cell Count Software (right panel). 
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standard VACV-specific immunostaining assay to confirm the data from 
plaque counting using the Hybrid Cell Count analysis assay. An equal 
number and very similar pattern of virus plaques were detected (Fig. 2C). 
These results indicate a surprisingly high number of single cell infection 
events, which closely correlated with the calculated number of non-plaque 
forming particles in the MVA-GFP-mCherry preparation.  
VACV reporter viruses reveal viral early gene expression in most non-
plaque forming infections 
To more precisely follow up the outcome of MVA-GFP-Cherry infections in 
DF-1, CEF, and HeLa cells grown in 6-well plates, we selected 30 single 
GFP positive cells at 12 hpi. We automatically monitored the selected 
infected cells in the monolayers via live cell imaging (Keyence Time Lapse 
Module) over a time period of 24 hours (Fig. 3). 
 In DF-1 cells, 20% of the selected single infected green fluorescent cells 
resulted in the formation of plaques, 5% of the single cells proceeded to 
late gene expression as indicated by red fluorescence, and 75% of the 
infected cells remained green, i.e. in early gene expression. We could 
confirm these findings in CEF cells, where 16.9% of the selected cells 
formed plaques, 10.6% shifted to red fluorescence without plaque 
development, and 72.5% remained single green fluorescent cells. As 
expected, MVA-GFP-mCherry infection of human HeLa cells did not result 
in detectable virus plaques. However, the overall ratio of infected green 
cells arrested at the early stage of gene expression (83.9%) to infected red 
cells exhibiting late gene expression (16.1%) was similar to the proportion 
observed in the avian cell cultures (Fig. 3A).  
Next, we analyzed infections with the replication-competent CVA-GFP-
mCherry in DF-1 and HeLa cells using the same experimental setting (Fig. 
3B). In DF-1 monolayers 10.1% of the selected single infected cells 
developed into typical plaques, 17.6% of the single cells displayed red 
fluorescence without formation of plaques, and 72.3% of the infected cells 
remained green. These results were comparable to those obtained with 
MVA-GFP-mCherry in DF-1 cell cultures. Interestingly, in HeLa cells 
replication-competent CVA-GFP-mCherry formed about three-fold more 
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plaques than seen in DF-1 cell infections. Overall, these data 
demonstrated that most tissue culture MVA or CVA infection events 
remain arrested at the level of viral early gene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Tracking single cell infection via live cell imaging.  
Single green fluorescent DF-1, CEF and HeLa cells, infected with sucrose-
cushion purified viral stock preparation of MVA-GFP-mCherry (A) or 
sucrose-cushion purified viral stock preparation of CVA-GFP-mCherry (B), 
were selected at 12 hpi and monitored for 24 hours in 30 minutes 
increments via Time Lapse Software. Each value represents the mean 
with SEM of at least three separate experiments. 
 
Here, we tested the composition and biological activities of virus particles 
present in standard MVA vaccine preparations. For the first time we used 
new reporter viruses expressing the fluorescent markers GFP and 
mCherry under the control of an early and late viral promoter. Over the 
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past few years VACV biology has greatly benefited from advances in 
genetic engineering and fluorescent imaging techniques. Recombinant 
viruses with fluorescently tagged viral proteins have been elegantly used 
to elucidate the cell-to-cell spread and intracellular movement of VACV 
particles (FRISCHKNECHT et al., 1999; HOLLINSHEAD et al., 2001; 
WARD & MOSS, 2001a). In addition, fluorescent reporter viruses serve in 
screening experiments for antiviral drugs (DAL POZZO et al., 2008). Here, 
our reporter viruses successfully monitored VACV infection progression of 
both plaque-forming and non-plaque-forming virions and identified active 
transcription of viral early and late genes.  
In infection research recombinant MVA viruses serve as candidate 
vaccines compatible with clinical use and industrial-scale production (for 
review see Volz 2016 Adv Virus Res, in press). The data quality required 
before initiating clinical trials include evaluation of the phenotypic 
properties of the vaccine virus preparations (European Medicines Agency. 
2010. Guideline on quality, non-clinical and clinical aspects of live 
recombinant viral vectored vaccines. EMA/CHMP/VWP/ 141697/2009).  
Sucrose-gradient purified preparations of conventional VACV are known to 
comprise about 10-fold more total particles than infectious particles, e.g. 
as counted by electron microscopy and measured by plaque tests 
(JOKLIK, 1962). Also in this study, using an industry-standard virus 
counter and our regular protocol for MVA titration (KREMER et al., 2012a), 
we found a majority (>70%) of non-plaque-forming virions in standard 
MVA vaccine sucrose-cushion purified preparations from CEF or DF-1 
cells, avian cell lines that are consistently used with MVA to amplify and 
purify normal titers from cell cultures.  
Similar “noninfectious” particles have been found with many mammalian 
viruses, but the biological activities associated with these particles have 
largely been ignored (MARCUS et al., 2009; PIERSON & DIAMOND, 
2012). Further characterizing these non-plaque-forming particles in MVA 
vector vaccine preparations seems relevant due to their potential role in 
inducing innate or adaptive immune responses (LOPEZ, 2014).  
When testing sucrose-cushion purified preparations of MVA-GFP-mCherry 
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or CVA-GFP-mCherry in tissue culture infections we detected an 
unexpectedly high number of single fluorescent cells. Such monitoring of 
the infection events shows that non-plaque-forming particles also activate 
viral gene expression, although most of these single cell infections are 
restricted to synthesizing early gene products.  
The de novo synthesis of early viral RNAs suggests that these non-plaque 
forming infections trigger innate immune signaling, as previously described 
for NFkB activation following VACV early transcription (MARTIN & 
SHISLER, 2009; WILLIS et al., 2011). Notably, our time lapse experiments 
allowed us to precisely follow the development of single viral plaques or 
the fate of single infected cells by observing the synthesis of GFP and 
mCherry (see video clips Fig. S3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3 Time Lapse videos depicting the fate of single green 
fluorescent DF-1 cells infected with MVA-GFP-mCherry: (A) Infection 
results in plaque formation with multiple cells proceeding from viral early 
(green fluorescence) to late (red fluorescence) gene expression (B) Single 
cell infection remains restricted to viral early gene expression as identified 
by green fluorescence (C) Single cell infection proceeds to viral late gene 
expression as identified by red fluorescence. 
 
IV. Results     39 
Regardless of the stage of viral gene expression (early or late) and the 
permissiveness for productive infection, many of the remaining single 
fluorescent cells underwent morphological changes, including phases of 
contraction with retractions of cell projections followed by cell rounding, 
membrane blebbing, and disintegration or detachment from the cell 
monolayer. Since the results from experiments with replication-competent 
CVA-GFP-mCherry confirmed the data seen for MVA-GFP-mCherry, we 
are confident about the general validity of these findings for infections with 
particles from different strains of VACV and possibly for infections with 
virions from other orthopoxviruses. 
The mechanistic reason(s) for the substantial portion of abortive infection 
events still remain unclear. One possibility is that VACV preparations 
commonly contain fractions of “defective” virions unable to initiate a full 
cycle of viral gene expression and productive virus replication. We 
examined the virus particles in our stock preparations by electron 
microscopy and detected only mature brick-shaped virions with normal 
morphology (data not shown). Yet, this apparent absence of malformed 
particles does not formally exclude the possibility of mutations blocking 
later stages of infections. Alternatively, the biology of the host cell is 
essential for the replication of VACV and it is tempting to speculate that 
simply the condition of the infected host cell determines the outcome of an 
infection. The activation of host cell signaling pathways e.g. involving the 
MAPKs (mitogen-activated protein kinases) ERK (extracellular signal-
regulated kinase) and JNK (Jun N-terminal kinase) has been shown to be 
critical for productive infection and VACV spread (DE MAGALHAES et al., 
2001; ANDRADE et al., 2004; WANG et al., 2004a). Moreover, the 
activation of these host signaling pathways is specifically modulated in the 
favor of virus replication by various poxvirus regulatory proteins (DE 
MAGALHAES et al., 2001; WANG et al., 2006; SCHWENEKER et al., 
2012; TORRES et al., 2016). These findings are used in the development 
of oncolytic poxviruses that better grow in tumor cells where such 
pathways are malignantly activated (BELL & MCFADDEN, 2014). Our 
observation of CVA-GFP-mCherry infection resulting in enhanced plaque 
formation in HeLa cells might be based on the preferential productive 
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replication of this virus in tumor cells (see Fig. 3B). 
There are two major infectious forms of VACV particles: the mature virions 
(MV) and the extracellular enveloped virions (EV) (MOSS, 2013b). MVs 
are infectious virions surrounded by a lipoprotein membrane that 
accumulate within the cytoplasm of VACV infected cells (CONDIT et al., 
2006). Since MV are the most abundant virion form present in vaccine 
preparations, the data obtained in our experiments might be essential for 
the quality control of MVA based vaccines. Both infectious forms, MV and 
EV, have distinct biological properties and activities: EV are responsible 
for efficient cell-to-cell spread and contribute to transmission within the 
host, while the MV play a key role in the transmission between the host 
animals (BLASCO & MOSS, 1992; CUDMORE et al., 1995; MOSS, 2012). 
Further experiments are needed to clarify on a possibly distinct role of EV 
infections on gene expression and plaque formation in different host cell 
substrates. 
In conclusion, our experiments confirm that infection with non-plaque-
forming particles of VACV results in gene expression. Despite the inability 
of these “defective” virus particles to induce plaque formation, these 
particles are still able to switch on early gene expression. Interestingly, 
already early work by Galasso and Sharp (1964) suggested that “non-
replicating” VACV particles enter cells and exert biological activities. More 
recently, UV-inactivated recombinant VACV is used to express early 
genes as nonreplicative vector in tumor immunotherapy (ZAJAC et al., 
2003). Thus, viral and recombinant early transcripts might serve to 
efficiently trigger innate immune responses and antigen production by 
recombinant vaccines similar to processes described for other vaccine-
induced activations of immunity. In addition, these findings indicate that 
the choice of early or early-late promoters is an appropriate approach to 
most practically activate vaccine-induced immunity. Finally, our results 
further support the ability of MVA-based vaccines to stimulate a balanced 
interplay between innate and adaptive immunity as the key to robust 
protection against a selected pathogen. 
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Materials and methods 
Cells  
DF-1, HaCat and MA-104 Jena cells were cultured in VLE Dulbecco’s 
MEM (Biochrom GmbH) supplemented with 10% heat inactivated fetal 
bovine serum (HI-FBS) (SIGMA), 1% Penicillin-Streptomycin (SIGMA) and 
2% Hepes-buffer (SIGMA). HeLa cells were maintained in Minimum 
Essential Medium Eagle (MEM) (SIGMA) containing 10% HI-FBS and 
antibiotics as described above. Primary chicken embryo fibroblasts (CEF) 
were prepared from 10-day-old chicken embryos (SPF eggs, VALO, 
Cuxhaven) and subsequently grown in MEM supplemented with 1% 
Penicillin- Streptomycin, 1% MEM non-essential amino acid solution 
(SIGMA) and 10% HI-FBS. All cells were maintained at 37°C in a 5% CO2 
atmosphere.  
Generation of recombinant viruses 
Recombinant MVA-GFP-mCherry was generated by homologous 
recombination as described previously (KREMER et al., 2012a) MVA F6 
(MEYER et al., 1991) served as the parental virus for generating MVA-
GFP, used as the backbone virus for constructing MVA-GFP-mCherry. 
Vector plasmid pLW73 was used to direct the insertion of GFP, under the 
transcriptional control of vaccinia virus promoter Pvgf, into the G1L/I8R 
insertion site of the viral genome. Pvgf (5’-
GTTTATATTACTGAATTAATAATATAAAATTCCCAATCTTGTCATAAA-3’; 
underlined A indicates transcriptional start site as described by Broyles et 
al., 1991.), a natural vaccinia virus promoter, controls the early expression 
of VACV ORF C11R mRNA that was recently reported to belong to the 
temporally first class of early genes (immediate-early class or E1.1 
subclusters) (ASSARSSON et al., 2008; YANG et al., 2010). Plasmid 
pIIIgptex served as the vector for inserting mCherry, placed under the 
vaccinia virus promoter P11, into Deletion III. Recombinant MVA was 
obtained by clonal isolation in plaque purifications using five to eight 
passages in CEF following the plasmid transfections. Finally, recombinant 
viruses were amplified in CEF. Screening for expression of the fluorescent 
proteins was used to identify and isolate recombinant viruses. Quality 
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control experiments were performed using standard methodology 
(KREMER et al., 2012a).  
The genetic identity and genetic stability of the reporter virus were 
assessed via PCR analysis of genomic viral DNA. The replicative capacity 
of the recombinant virus was confirmed by one-step and multiple-step 
growth experiments in CEF, DF-1, HeLa and HaCat cells. CVA-GFP-
mCherry was constructed in a similar manner to MVA-GFP-mCherry, but 
the fully replication-competent virus CVA152 (WAIBLER et al., 2009) was 
used as the parental virus and the propagation was carried out in MA-104 
cells. CVA152 is a direct ancestor virus of MVA and its genome sequence 
is identical to MVA at the insertion sites Deletion III and I8R/G1L. Sucrose-
cushion purified virus stocks of MVA-GFP-mCherry and CVA-GFP-
mCherry were generated by ultracentrifugation through a 36% sucrose 
cushion, followed by resuspension in 10 mM Tris buffer pH 9 using 
standard procedures as described in (KREMER et al., 2012a) and 
(JOKLIK, 1962). 
Quantification of virus 
Plaque assay 
Viral plaque forming units (PFU) were determined via standard plaque 
assays, as described in Kremer and coworkers (KREMER et al., 2012a). 
Briefly, confluent CEF cell monolayers in 6-well plates were infected with 
serial 10-fold dilutions of the viruses. After 2 h of incubation at 37°C, the 
cells were washed once with phosphate buffered saline (PBS) and 
incubated with fresh medium containing 2% HI-FBS at 37°C for two days, 
followed by a vaccinia specific immunostaining. Here, the infected cells 
were fixed in acetone-methanol (1:1) for 5 min, washed with PBS and 
incubated for 60 min with a polyclonal rabbit anti-vaccinia virus antibody. 
After an additional washing step (PBS), the cells were incubated with 
peroxidase-conjugated AffiniPure goat anti-rabbit secondary antibody for 
60 min. Plaques were visualized using TrueBlue peroxidase substrate 
solution (KPL), counted and calculated as described previously (KREMER 
et al., 2012a). All virus titrations were performed in duplicate and repeated 
at least three times.  
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Total virus particle counts 
Total virus particles were estimated using ViroCyt VirusCounter 3100 
following the manufacturer’s instructions (ViroCyt, Bloomfield, CO). Briefly, 
the sucrose-cushion purified virus samples were diluted 1:200 and 1:400 
in ViroCyt sample dilution buffer. Subsequently, 300 µl of each sample 
were incubated with 150 µl Combo Dye solution, a combination of two 
fluorescent dyes specific for proteins and nucleic acids (STOFFEL et al., 
2005). After 30 min of light-protected incubation at room temperature, the 
virus particles were quantified in the virus counter. Simultaneous detection 
of both fluorescent signals using the virus counter’s dual channel flow 
cytometer was measured as one virus particle. Inter-sample washes, 
followed by a cleanliness control run were performed between each 
sample analysis, and medium from uninfected CEFs was used as a 
negative control. Total virus particle concentration was recorded as virus 
particles per ml (VP/ml) and determined for at least three times per virus 
sample. 
Fluorescent microscopy 
Fluorescent images were obtained using an inverted fluorescence 
microscope (Keyence BZ-X700) with a x20 Plan Fluor NA 0.45 Ph1 
objective and a z-section setting. Emission of GFP filter (excitation 
wavelength 470/40 nm, absorption wavelength 525/50 nm) and TexasRed 
filter (excitation wavelength 560/40 nm, absorption wavelength 630/75 nm) 
were used for detecting green and red fluorescence. Raw imaging data 
were processed and analyzed with BZ-X Analyzer Software. 
Hybrid cell count 
The ratio of single infected fluorescent cells to plaque-forming fluorescent 
units was assessed during MVA-GFP-mCherry infection in permissive 
cells by culturing CEF and DF-1 cells in 96-well plates. Each well was 
infected at an m.o.i. of 0.01 and received 100 µl of inoculum. After 30 min 
incubation at 4°C (cold start), cells were washed with PBS three times and 
incubated at 37°C with 200 µl fresh medium containing 2% HI-FBS. 24 h 
after infection multiple fluorescent and bright-field images of the infected 
wells were acquired using a 20x objective, and then stitched together via 
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the Keyence Merge function. Afterwards a vaccinia specific 
immunostaining of the captured wells was performed, as described above 
(Plaque assay). Bright-field images of these wells served as controls. The 
total single fluorescent cell count was quantified using single extraction 
function of the Hybrid Cell Count Software (Keyence Hybrid Cell Count 
Module, BZ-H3C) and total foci were counted manually.  
Live cell imaging 
For live cell imaging, DF-1, CEF and HeLa cells cultured in 6-well plates, 
were infected with a sucrose-cushion purified viral stock preparation of 
MVA-GFP-mCherry or a sucrose-cushion purified viral stock preparation of 
CVA-GFP-mCherry at an m.o.i. of 0.005 via cold start as described above. 
After three washing steps with PBS, 2 ml fresh medium containing 2% 
FBS was added and the cells were incubated at 37°C. At 12 hpi about 30 
single green fluorescent cells were selected for each separate experiment. 
The development of the single infected cells was observed in 30 minutes 
increments for a further 24 hours using Keyence Time Lapse Module, BZ- 
H3XT. Time lapse analysis was performed at 37°C with 5% CO2 
concentration using an incubation chamber (Tokai Hit, Incubation Systems 
for Microscopes) to allow 24 h recording. All time lapse experiments with 
recombinant MVA and CVA viruses were performed at least three times. 
Western blot analysis 
Chicken embryo fibroblasts were infected at an m.o.i. of 10 with MVA-
GFP-mCherry and CVA-GFP-mCherry in the absence or presence of 
cytosine arabinoside (AraC, 1 mg/ml). MVA wild type or mock-infected 
cells served as controls. Total cell extracts were prepared at 24hpi. After 
separating by 10% SDS-PAGE proteins were analyzed via Western Blots 
using anti-GFP rabbit fraction antibody (life technologies, 1:250) and anti-
mCherry rat fraction antibody (kindly provided by Elisabeth Kremmer, 
Helmholtz Zentrum München, 1:10 dilution) as primary antibody. For 
detection of GFP and mCherry via MicroChemisystems (biostep), anti-
rabbit HRP-conjugated antibody (Sigma, 1:5000 dilution) and goat anti-rat 
HRP-conjugated antibody (BioLegends, 1:2000) were used as secondary 
antibodies. 
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Statistical analyses 
The differences in virus particle titres were assessed for statistical 
significance with GraphPad Prism version 5 software (GraphPad software, 
San Diego, USA); using the Mann-Whitney U test and P-values less than 
0.05 were considered to be statistically significant. 
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V. DISCUSSION 
 
The heterogeneity of MVA and VACV populations in terms of the particle’s 
infectivity has been known for many years. The plaque-forming particles 
constitute a minority in purified MVA and VACV viral stock preparations. 
However, the majority of the particles form a subpopulation whose effect 
for the biology of infections is still uncertain. The objective of the current 
study was to provide new insights in the biological activities of this 
unknown particle subset. Our newly constructed reporter viruses, MVA-
GFP-mCherry and CVA-GFP-mCherry, enabled us to analyze the 
complexity of MVA and CVA infections in life-time. The expression of GFP 
and mCherry, controlled by specific early and late promoters, allowed for 
detection of productive and abortive infections as well as for the specific 
level of gene expression. Our in vitro data showed that a minority of the 
viral particles replicated productively. The fraction of non-plaque forming 
(NPF) particles was likely represented by infections that were unable to 
pass beyond the stage of early gene expression. As these abortive 
infections constituted a surprisingly high proportion of the total infections, 
we assume that nearly all virions of MVA and CVA have the capability to 
activate at least the stage of early gene expression.  
 
Population heterogeneity of other viruses 
The presence of NPF-particles has been observed for decades in the 
population of several RNA and DNA viruses (WILDY & WATSON, 1962; 
RAINBOW & MAK, 1970). Depending on the specific biology of the 
viruses, the ratio of particles to infectious units varies from 1 to 1000 
(Table1). Regarding the high values of particle-to-PFU ratio, the question 
arises whether these NPF-particles have certain viral functions that may 
affect the course of viral infections.  
The first biologically active but “non-productive” form of virus particles was  
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       Virus   
Particle-to-PFU 
 ratio 
   
 Polyomaviridae 
  
   Polyomavirus 38-50 
   Simian virus 40 100-200 
 Adenoviridae 
   Adenovirus type 12 320
1 
 Poxviridae 
   Vaccinia virus 6-7
2 
   MVA 4-5
2 
 Orthomyxoviridae 
   Influenza virus 20-50 
 Picornaviridae 
   Poliovirus 30-1.000 
 Reoviridae 
   Reovirus 10 
 Alphaviridae 
   Semliki Forest virus 1-2 
 Herpesviridae 
   Herpes simplex virus 50-200 
 
 
Table 1: Particle-to-PFU ratio of different viruses  
(Principles of Virology, Flint et al., Third Edition, ASM Press; modified)  
1 (Lülf et al., 2016), 2 (GREEN et al., 1967) 
                                                               
detected by Henle and Henle in the 1940s, who described the now widely 
known defective interfering (DI) particles of influenza virus populations 
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(HENLE & HENLE, 1943). This fraction of particles constitutes a 
subpopulation with special properties: they contain smaller units of the 
genome, their replication depends on the presence of a functional 
standard virus, they interfere with the propagation of the “helper viruses” 
during coinfection and the amount of DI particles increase during 
passages at high multiplicity of infection (HUANG & BALTIMORE, 1970). 
Over the years, DI particles were detected in vitro in many other virus 
families, especially in RNA viruses such as vesicular stomatitis virus 
(HACKETT et al., 1967), sendai virus (KINGSBURY et al., 1970) and polio 
virus (COLE et al., 1971). While it has long been known that VACV 
preparations exhibit a significant difference between total virus particles 
and NPF-particles, such DI particles have never been found in POXVs 
(ISAACS, 1957; GALASSO & SHARP, 1963).  
In addition to DI particles, a further subpopulation of NPF-particles can be 
detected in Influenza A virus - the semi-infectious (SI) particles (BROOKE, 
2014). This fraction is spread-incompetent and non-interfering, but has 
infectious potential. It can be isolated in vitro as well as in vivo. The SI 
particles are able to infect cells and express restricted numbers of 
essential viral proteins. Depending on which proteins are synthesized, 
these particles activate different innate signaling pathways. Thus, SI 
particles can be assigned to distinct, detected subpopulations: 
noninfectious cell killing particles (niCKP) (NGUNJIRI et al., 2008; 
BROOKE, 2014), IFN-inducing particles and IFN-induction suppressing 
particles (MARCUS et al., 2005; NGUNJIRI et al., 2012; BROOKE, 2014). 
Among the NPF-virions in CVA and MVA preparations, we also 
determined differences in their ability to achieve the levels of gene 
expression (either early gene expression or until late gene expression). It 
is also very likely that the activation of early or early and late stages in the 
VACV molecular life cycle initiate different innate signaling pathways.  
Among the DNA viruses, NPF-particles capable of a range of biological 
activities can also be detected. For human adenoviruses it is known that 
such particles have lower density compared to functional infectious virions 
due to deletions of their viral genome. For this reason, the subpopulations 
can be easily analyzed by separating them through centrifugation in a 
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density gradient. Thus, some viral functions like cytolysis and tumor (T) - 
antigen production could also be attributed to the fraction of NPF-virions of 
adenovirus Type 12. (RAINBOW & MAK, 1970; MAK, 1971). This goes in 
line with studies of defective virus particles of Simian Virus 40, which are 
able to induce virus-specific T antigens (UCHIDA et al., 1968). Studies of 
the NPF-particles with limited biological functions, or rather DI-particles of 
various DNA and RNA viruses, indicated that their genomes, when 
compared with genomes of standard plaque-forming-particles, differ in 
terms of their size. The morphology and structural proteins of the different 
particle subpopulations appear identical. (PATTNAIK & WERTZ, 1991; 
DIMMOCK & EASTON, 2014; FRENSING, 2015) In the field of VACVs 
studies analyzing the biological activities of NPF-particles are very limited. 
In the 1960s Galasso and Sharp had a very early suspicion that all NPF-
particles are at least capable of infecting cells (GALASSO & SHARP, 
1964). This approach had not yet been further pursued until very recently. 
However, the current study has confirmed the presumption of Galasso and 
Sharp. Indeed, the results indicate that essentially all NPF-particles are 
capable of reaching the stage of early gene expression. This may have 
several implications for the future of infection research, especially with 
regard to MVA as a vaccine platform.  
Detailed studies will be required to understand the mechanisms that are 
crucial to execute the observed abortive infection or rather the origin of the 
NPF-particles. One interesting aspect could be the evaluation of mutations 
within the NPF-particles’ genome. Depending on the particular proteins 
that can be expressed, the NPF-particles might have the potential to rise 
beyond the stage of early gene expression. However, the abortive events 
might also result from the interactions with the respective host. On a 
cellular level the specific activation status of the cell might restrict VACV 
life cycle to the early stage. In addition this might also be induced by the 
activation of specific cell signaling pathways that are activated by VACV 
proteins, such as the well-studied vaccinia virus growth factor (VGF) or the 
regulatory VACV protein O1 targeting the ERK signaling pathway 
(BULLER et al., 1988; SCHWENEKER et al., 2012). 
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Impact of the NPF-virions on the biology of infections 
Although the NPF-particle subpopulation of different mammalian viruses 
was previously thought to have only restricted viral functions in vitro, there 
is growing evidence that this fraction contributes to the pathogenesis of 
infections in vivo. The induction of the innate immune response appears to 
be especially affected by these NPF-particles (FRENSING, 2015). During 
viral infection, virus-associated molecules such as double-stranded RNA 
(dsRNA) are recognized through the host’s pattern-recognition receptors. 
These induce a signaling cascade which specifically activates among 
other things the expression of type I interferons via different transcription 
factors such as NFkB (KAWAI & AKIRA, 2006). This in turn initiates the 
expression of antiviral proteins that interfere with viral replication. 
Especially, the DI genomes of some viruses seem to induce the innate 
immune response. For instance, the copy-back DI genomes of the Sendai 
virus, which have complementary ends, are able to form long stretches of 
dsRNA. Strahle et al. state that this presumably explains the strong 
interferon (IFN) beta activation through the Sendai virus (STRAHLE et al., 
2006). Furthermore, it has been shown that Sendai virus and Influenza A 
virus DI genomes are naturally generated in lungs of infected mice and 
also contribute to an IFN induction in vivo (TAPIA et al., 2013).  
However, the NPF-particles of MVA and CVA preparations described in 
the current study have different biological properties in comparison to DI 
particles. Virtually all of these NPF-particles are able to enter cells and 
switch on the early stage of gene expression. It seems very likely that this 
has an impact on the course of infections. There are several studies that 
provide insight on the early phase of the MVA life cycle triggering cellular 
signaling pathways.  
Regarding the cellular basis of the adaptive immune response, it has been 
shown that recombinant genes expressed under the control of early VACV 
promoters induce greater cytotoxic CD8+ T cell responses compared to 
late promoters (COUPAR et al., 1986; ZHOU et al., 1991; BRONTE et al., 
1997). Generally, the induction of a strong T-cell response has become 
increasingly important in vaccine development as several studies 
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confirmed that T-cell responses play a critical role for the immunity against 
infectious diseases (PANTALEO & KOUP, 2004; KREMER et al., 2012b; 
ALTENBURG et al., 2014). Moreover, it has been reported that the VACV 
gene expression arrest at the early phase of the viral molecular life cycle 
in human and murine dendritic cells proposing to express target antigens 
under the control of early promoters (BRODER et al., 1994; BRONTE et 
al., 1997; SUBKLEWE et al., 1999; KASTENMULLER et al., 2006). In 
addition, these dendritic cells are essential for the cross-presentation of 
viral antigens (SIGAL et al., 1999; ACKERMAN et al., 2003; LARSSON et 
al., 2004), which is relevant for protection against viruses that do not 
directly infect antigen-presenting cells. Here, exogenous antigens, 
avoiding the endogenous processing pathway, are taken up via 
phagocytosis and displayed to cytotoxic CD8+ T cells via major 
histocompatibility complex class I molecules (CHAPLIN, 2010). The use of 
early promoters has also been reported to be crucial for the reactivation of 
memory T-cells. Kastenmüller et al. demonstrated that the number of 
specific CD8+ T cells during boost vaccination was highly affected by the 
timing of antigen expression. They suggest that the competitions of CD8+ 
T cell activities are responsible for this outcome (KASTENMULLER et al., 
2007). 
 
The early phase of MVA’s life cycle influences not only the adaptive 
immunity but has also impact on the innate immunity. In general, dsRNA 
plays an important role in the activation of the innate immune response 
against viral infections (JACOBS & LANGLAND, 1996; HALLER et al., 
2006). For VACV, the majority of complementary RNA arises during the 
intermediate and late phase of VACV replication while little complementary 
RNA is synthesized in early stages (COLBY et al., 1971; BOONE et al., 
1979). This might indicate that the majority of the appropriate signaling 
pathways are activated in the late stage of infection. However, a recent 
study demonstrated that an early event during MVA replication is capable 
of activating NFkB transcription factors, which is based on a dsRNA 
dependent protein kinase (PKR)-mediated process (HAYDEN et al., 2006; 
LYNCH et al., 2009). As dsRNA is supposed to be one of the major stimuli 
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of the PKR, the authors presume that the induction of PKR might be 
caused by the small quantities of dsRNA produced at the early phase 
during the MVA life cycle (GARCIA et al., 2006; LYNCH et al., 2009). A 
further study reported that MVA proteins, synthesized in the early phase, 
possess NFkB activation function (MARTIN & SHISLER, 2009). Another 
study found that MVA is able to activate human dendritic cells via an NFkB 
dependent process (DRILLIEN et al., 2004). In contrast to this, it has been 
shown that both the replication-competent VACV strain Western Reserve 
and a cowpox virus prevent NFkB activation during infections of human 
embryonic kidney cells, as they encode proteins that inhibit the related 
signaling pathways (LYNCH et al., 2009).  
Generally, Orthopoxviruses developed a multitude of strategies to evade 
the host cell immune response. VACV genes encode accessory proteins 
that interfere with host cytokines, such as TNF, in order to inhibit the 
activation of transcription factors (HU et al., 1994; SMITH et al., 1996; 
PICKUP, 2007). An important distinction is that it has been shown that 
MVA lacks several of these immune evasion factors, as most of the 
corresponding genes are fragmented (ANTOINE et al., 1998; 
BLANCHARD et al., 1998).  
Another indication that the early phase of MVA’s life cycle contributes 
significantly to triggering the innate immune response can be seen in the 
early induction of interferon alpha during MVA infection. Waibler et al. 
demonstrated that the secretion of IFN alpha in MVA infected bone 
marrow derived plasmacytoid dendritic cells is fully independent of viral 
replication as well as intermediate and late gene expression since an 
inhibition of viral replication did not result in a decrease of IFN-alpha levels 
(WAIBLER et al., 2007). In line with these results, it was reported that 
interleukin (IL) -1beta and IL-8, both pro-inflammatory cytokines, as well 
as IFN-beta production were not affected in THP-1 cells which were 
infected with UV- treated MVA (DELALOYE et al., 2009). Dai et al. 
postulate that viral DNA, released upon MVA entry, triggers the type I IFN 
production in murine conventional dendritic cells and, furthermore, 
Delaloye et al. assume that the MVA envelope or a core protein is one of 
the responsible triggers for the IL-8 production (DELALOYE et al., 2009; 
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DAI et al., 2014). These findings indicate that MVA infection induces host 
cell cytokine production even before the viral early protein synthesis. 
Moreover, MVA is able to induce significant type I interferon responses 
upon in vivo infection of mice whereas a systemic release of type I IFN 
cannot be detected following the infection with conventional replication-
competent VACV. Interestingly enough, the same study showed that two 
MVA ancestor viruses, CVA-152 and CVA-386 which were isolated after 
the 152nd and 386th CEF passage, do not induce IFN alpha while CVA 
386 induces IFN beta. Waibler et al. relate this to the consecutive loss of 
immune evasion factors during MVA attenuation (WAIBLER et al., 2009). 
Taken together, these studies demonstrate that MVA activates the innate 
immune response very early during the viral life cycle. Thus, the ability of 
MVA’s NPF-particles to enter cells and to activate the early gene 
expression may be an important factor in triggering cellular signaling 
pathways. Indeed, it seems to be very likely that the biological properties 
of the NPF-particles contribute to MVA’s strong intrinsic immunogenicity. 
The viral function of the NPF-particles, as a stimulus for the innate 
immune response, may enhance the efficacy of MVA-based vaccines. 
Hence, the NPF-particles might act as a natural adjuvant. Furthermore, 
the work of others reporting efficient antigen-specific cytotoxic CD8+ T cell 
immune responses of viral antigens expressed during the early phase of 
the VACV molecular life cycle, indicate the relevance of the early gene 
expression for the stimulation of the adaptive immunity (COUPAR et al., 
1986; ZHOU et al., 1991; BRONTE et al., 1997; KASTENMULLER et al., 
2007). These findings and our results clearly emphasize the use of early 
or early-late promoters for recombinant antigens to influence an efficient 
and optimal innate and adaptive immune response. 
 
MVA-GFP-mCherry – novel tool for basic research 
The construction of MVA-GFP-mCherry constitutes a novel approach for 
tracking viral functions. Quality controls including determination of genetic 
stability and replication capacity confirmed the suitability of MVA-GFP-
mCherry for its use as a reporter virus. Various issues concerning the 
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virus life cycle, such as virus replication, host range effects and the impact 
of host factors on the viral replication, can be pursued by using this 
reporter virus. This was nicely shown by the current study. Here, MVA-
GFP-mCherry provided simultaneous monitoring of the early and late gene 
expression during MVA infections, which enabled the visualization of the 
well-known cascade-like gene expression of POXVs in real time (MOSS et 
al., 1991). Another useful aspect of the reporter virus is the capability to 
differentiate between productive and abortive infections in various cell 
cultures in vitro and also to investigate the infection of target cells/tissues 
in vivo. Especially with regard to the characterization of the particle 
population it is very helpful to gain insight into the general replicative 
potential of single particles. MVA-GFP-mCherry even enables analyzing 
the particles viral function in more detail since the fluorescent reporter 
proteins indicate which level of the viral life cycle is achieved. The certain 
stage of arrest indicated that the virus probably lacks the competence to 
express essential proteins for the next step of gene expression.  
For several decades, changes in the course of gene expression had to be 
determined via Western or Northern blotting as well as metabolic labeling 
analysis. These well-established traditional methods can provide 
information regarding changes in each stage of the viral expression 
cascade. However, they are not able to attribute the particular steps of 
gene expression to single cell infection events. Thus, abortive infections 
remain undetected. In contrast to this the reporter virus allows tracking of 
individual infection events as well as the determination of the point of 
inhibition due to the usage of stage specific promoters. Another benefit of 
the application of MVA-GFP-mCherry is the time-saving aspect. Due to 
direct and simultaneous microscopic observation, analysis of the viral life 
cycle using the reporter virus is much faster in comparison to traditional 
indirect methodologies.  
There are various applications for which the reporter virus can be used as 
a tool for basic research. For instance, MVA-GFP-mCherry mutant viruses 
lacking certain genes can be generated to easily analyze the impact of 
specific viral proteins on the viral life cycle. In addition, reconstruction of 
defective genes in the reporter virus genome can be applied to study the 
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function of individual VACV genes and their contribution to the viral 
replication in non-permissive cells. The reporter virus constitutes an 
innovative tool, especially for the analysis of cellular host factors and their 
involvement in the virus-host interactions. For example, monitoring the 
effect of cellular gene knockdowns on the viral expression cascade helps 
to further the knowledge of the function of these host factors. 
All in all, the newly constructed reporter virus has been proven to be a 
powerful tool in studying the progression of viral spread at the level of 
individual particle infections. The virus shed new light on the largely 
ignored role of NPF-particles during MVA infections and it might further 
help to gain a better understanding of the basic mechanisms by which 
MVA’s cell tropism and host range are controlled. 
 
Future perspectives 
The initial experiments with MVA-GFP-mCherry confirmed its ability to be 
used as a reporter virus in in vitro studies. However, in vivo imaging of 
fluorescent reporter viruses has also been established in various animal 
models for several viruses, such as canine distemper virus (VON 
MESSLING et al., 2004) and measles (LEMON et al., 2011). Thus, MVA-
GFP-mCherry might not only be useful for in vitro characterizations but 
also for in vivo studies. This strategy might be beneficial for addressing 
issues, particularly those related to biosafety and environmental safety, in 
terms of development and marketing authorization of recombinant MVA 
products. In particular, the evaluation of the biodistribution and clearance 
of genetically modified viruses in vaccinated individuals is an important 
aspect in the European guidelines of live recombinant viral vectored 
vaccines (European Medicines Agency. 2010. Guideline on quality, non-
clinical and clinical aspects of live recombinant viral vectored vaccines. 
EMA/CHMP/VWP/ 141697/2009). Biodistribution in patients and virus 
shedding from patients are major safety parameters for considering the 
potential risk of vector dissemination into the environment (BALDO et al., 
2013). In addition to the type of viral vector, the application route is also an 
essential factor that contributes to the distribution within the body. So far 
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there are only a few biodistribution and shedding studies of MVA-based 
vector vaccines available (RAMIREZ et al., 2000; STITTELAAR et al., 
2001; GOMEZ et al., 2007). In this context, the reporter virus MVA-GFP-
mCherry might facilitate the study of viral distribution in in vivo models. 
Macroscopic fluorescence imaging may indicate the organ-specific 
distribution of MVA while microscopic imaging can provide information 
about MVA’s specific cell tropism. Thus, with the help of MVA-GFP-
mCherry the viral distribution might be tracked from different sites of 
application to dispersion and clearance within the patients. One particular 
aspect that would be very interesting to explore with the help of this 
reporter virus is the fate of MVA in the chicken model – the ancient host of 
MVA.      
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VI. SUMMARY 
Fluorescent Reporter Viruses Identify Non-Plaque-Formig Virions of 
Vaccinia Virus to Activate Viral Gene Expression 
The use of viruses as vaccine backbones has become more and more 
important for innovative vaccine development over the last decades. The 
particular ability to induce both the humoral as well as the cellular immune 
response has been considered to be a tremendous benefit of viral vector 
platforms. Thus, viral vaccine vectors are deemed to be an attractive 
alternative to traditional vaccine strategies. In this context, the Modified 
Vaccinia virus Ankara (MVA) has been proven to be a very promising viral 
vaccine platform due to its capability of inducing an extraordinarily strong 
immune response along with its excellent safety profile. Concerning the 
clinical testing of recombinant MVA vaccine candidates, knowledge about 
the phenotypic and biological properties of the virus preparation is 
essential.  
Interestingly virus preparations of vaccinia virus (VACV) and also MVA 
seem to comprise substantially more total particles than infectious 
particles as seen in vitro in cell culture. Here, the majority of the viral 
particles constitute a subpopulation without the ability to form plaques in 
permissive cells. However, there is not much known about the biological 
activity as well as the biological functionality of these particles. 
With regard to the unknown biological activities of the non-plaque (NPF) 
forming particles, the objective of this study was to investigate their effect 
on the biology of infections. For this purpose we generated a recombinant 
MVA and parental Chorioallantois Vaccinia virus Ankara (CVA) reporter 
viruses which express fluorescent proteins under the transcriptional 
control of early and late specific promoters. These reporter viruses allowed 
us to elegantly follow single infections in infected cell culture – in other 
words, the potential of individual virions to activate viral gene expression. 
Hence, we were able to differentiate between productive and abortive 
infections in MVA permissive cells and beyond that to identify the level of 
gene expression. Our in vitro studies in several cell lines indicated that 
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nearly all virions are infectious and are able to at least switch on the early 
gene expression. These novel findings shed new light on this 
“indiscernible” subpopulation of NPF-particles. 
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VII. ZUSAMMENFASSUNG 
Fluoreszierende Reporterviren identifizieren nicht-Plaque-bildende 
Virionen mit biologischer Aktivität in Vaccinia virus Präparationen 
Die Verwendung von Viren als Impstoffvektoren hat in den letzten 
Jahrzehnten im Bereich der Impfstoffentwicklung zunehmend an 
Bedeutung gewonnen. Vor allem die Fähigkeit sowohl die humorale als 
auch die zelluläre Immunantwort zu induzieren, wird als enormer Vorteil 
der viralen Impfstoffplattformen angesehen. Somit stellen virale 
Impfstoffvektoren eine attraktive Alternative zu den traditionellen 
Impfstrategien dar. In diesem Zusammenhang hat sich das modifizierte 
Vaccinia virus Ankara (MVA) als sehr viel versprechende 
Impfstoffplattform erwiesen. Dies ist besonders auf die starke Aktivierung 
der angeborenen Immunantwort sowie das ausgezeichnete 
Sicherheitsprofil zurückzuführen. Im Hinblick auf den klinischen Einsatz 
von rekombinanten MVA Impfstoff-Kandidaten sind fundierte Kenntnisse 
über die phänotypischen und biologischen Eigenschaften von gereinigten 
Viruspräparationen essentiell. 
Die Mehrheit der Viruspartikel in aufgereinigten MVA- und Vaccinia virus 
(VACV)-Präparationen ist einer Fraktion zugehörig, die nicht in der Lage 
ist in permissiven Zellen Plaques zu bilden. Dieses Phänomen ist schon 
seit Jahrzehnten bekannt, jedoch ist die biologische Aktivität und dessen 
Auswirkung auf die Infektion bislang noch nicht untersucht worden.  
Angesichts der Frage ob diese nicht-Plaque-bildenden (NPF) Partikel 
auch die Immunogenität oder Wirksamkeit eines MVA-Impfstoffes 
beeinflussen könnten, wurde die biologische Aktivität dieser Partikel im 
Rahmen der vorliegenden Arbeit untersucht. Hierzu wurden rekombinante 
Reporterviren entwickelt. Die Gensequenzen des grün fluoreszierenden 
Proteins (GFP) und eines rot fluoreszierenden Proteins (mCherry) wurden 
in das MVA Genom sowie in das Chorioallantois Vaccinia virus Ankara 
(CVA) Genom, dem Ursprungsvirus von MVA, integriert. GFP und 
mCherry wurden dabei unter der Transkriptionskontrolle eines VACV-
spezifischen frühen sowie eines späten Promotors produziert. Dies 
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ermöglichte uns einzelne Infektionsereignisse in infizierten Zellkulturen 
genau zu verfolgen, sodass wir zwischen produktiven und abortiven 
Infektionen differenzieren und die erreichte Stufe der viralen 
Genexpression bestimmen konnten. Unsere in vitro Studien in 
verschiedenen Zellen deuten darauf hin, dass nahezu alle MVA sowie 
CVA Virionen in der Lage sind Zellen zu infizieren und die Synthese viraler 
Genprodukte zu starten. Diese Erkenntnisse geben einen neuen Einblick 
auf die bisher „unsichtbare“ Subpopulation der NPF-Partikel und legen 
deren Beitrag zur Wirksamkeit von MVA-Impfstoffpräparationen nahe. 
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IX.  ABBREVIATION 
AraC    Cytosine arabinoside 
CAM    Chorioallantois membrane 
CEF    Chicken embryo fibroblasts 
CVA    Chorioallantois Vaccinia virus Ankara 
DI    Defective interfering 
DNA     Deoxyribonucleic acid 
dsDNA   Double-stranded DNA 
ERK    Extracellular signal-regulated kinase 
EV    Enveloped virion 
GFP    Green fluorescent protein 
HI-FBS   Heat inactivated fetal bovine serum 
HIV    Human immunodeficiency virus 
hpi    Hours post infection 
IFN    Interferon 
IL    Interleukin 
INF    Interferon 
ITRs    Inverted terminal repeats 
IV    Immature virion 
JNK    Jun N-terminal kinase 
kb                             Kilobase  
kDa                     Kilodalton 
MAPKs   Mitogen-activated protein kinases 
MEM    Minimum Essential Medium Eagle 
IX. Abbreviation     92 
MERS   Middle East respiratory syndrome 
MERS-CoV   Middle East respiratory syndrome coronavirus 
MOI     Multiplicity of infection 
MPXV    Monkeypox virus 
MV    Mature virion 
MVA     Modified Vaccinia virus Ankara 
niCKp    Noninfectious cell killing particle 
NPF    Non-plaque-forming 
NYVAC   New York attenuated vaccinia virus 
ORF     Origin of replication 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction  
PFU    Plaque-forming unit 
PKR    Double-stranded RNA-dependent protein    
                                          kinase 
PmH5    Modified promoter H5 
POXV    Poxvirus 
RNA    Ribonucleic acid 
SI    Semi infectious 
TICD50   Tissue culture infectious dose 50 
TNF    Tumor necrosis factor alpha 
VACV    Vaccinia virus 
VP    Virus particles 
WHO    World Health Organization 
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